AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD) - Full Text View

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00240331

Purpose

The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.

Condition	Intervention	Phase
Renal Failure	Drug: 10mg Rosuvastatin	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events (AURORA). A Double Blind, Randomised, Phase 3b, Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival & Cardiovascular Events When Given to Subjects With End-stage Renal Failure on Chronic Haemodialysis Treatment

Resource links provided by NLM:

MedlinePlus related topics: Dialysis Heart Attack Kidney Failure

Drug Information available for: Rosuvastatin calcium Rosuvastatin

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Number of Randomised Participants That Died From Any Cause. [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
Number of Randomised Participants That Died From Cardiovascular Cause [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
Number of Randomised Participants That Died From Non Cardiovascular Cause [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death) [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis. [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations). [ Time Frame: Events were reported continously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]

Enrollment:	2776
Study Start Date:	July 2004
Study Completion Date:	October 2008

Eligibility

Ages Eligible for Study:	50 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female subjects with end-stage renal failure aged 50-80 years, who have received regular haemodialysis treatment for at least 3 months

Exclusion Criteria:

Subjects will have no underlying condition that is expected to limit survival to less than 1 year and is also unrelated to end-stage renal disease (ESRD). Subjects should not have received a statin therapy within the past 6 months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00240331

Show 241 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

AstraZeneca Crestor Medical Sciences Director, MD

AstraZeneca

More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 Apr 2;360(14):1395-407. Epub 2009 Mar 30.

Study ID Numbers:	4522IL/0096, D3562C00096
Study First Received:	October 16, 2005
Results First Received:	September 29, 2009
Last Updated:	September 29, 2009
ClinicalTrials.gov Identifier:	NCT00240331 History of Changes
Health Authority:	Sweden: Medical Products Agency

Keywords provided by AstraZeneca:

End Stage Renal Failure

Additional relevant MeSH terms:

Antimetabolites
Renal Insufficiency
Molecular Mechanisms of Pharmacological Action
Antilipemic Agents
Kidney Failure, Chronic
Enzyme Inhibitors
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Pharmacologic Actions
Rosuvastatin
Urologic Diseases
Renal Insufficiency, Chronic
Therapeutic Uses
Kidney Diseases
Kidney Failure

ClinicalTrials.gov processed this record on February 09, 2010